Mantle Cell Lymphoma
Conditions
Brief summary
The OASIS II trial is a multicentre, open label, randomized phase II trial. We will compare the efficacy of Ibrutinib/anti-CD20 Ab versus Ibrutinib/anti-CD20 Ab/Venetoclax given as fixed duration combinations in newly diagnosed Mantle Cell Lymphoma (MCL) patients (≥ 18 years and \< 80 years of age). Treatment duration of Ibrutinib and Venetoclax will be a maximum of two years. Patients will be treated with CD20 Ab for 3.5 years. The primary aim is to assess MRD status at 6 months in both arms.
Interventions
DRUGIbrutinib 560 mg
560mg/d continuously from C1D2 to end C24
DRUGVenetoclax 10 MG Oral Tablet [Venclexta]
20mg/d from C2D1 to C2D7
DRUGVenetoclax 50 MG Oral Tablet [Venclexta]
50mg/d from C2D8 to C2D14
DRUGVenetoclax 100 MG Oral Tablet [Venclexta]
100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
Sponsors
The Lymphoma Academic Research Organisation
Institute of Cancer Research, United Kingdom
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1. Patient is ≥ 18 years and \< 80 years of age at the time of signing the informed consent form (ICF). 2. Patient understood and voluntarily signed and dated an ICF prior to any study-specific assessments/procedures being conducted. 3. Patient willing and able to adhere to the study visit schedule and other protocol requirements 4. Women of childbearing potential must have negative results for pregnancy test prior to study treatment start and agree to abstain from breastfeeding during study participation and at least 18 months after the last drug administration 5. Men or women of reproductive potential agree to use acceptable method of birth control during treatment and for eighteen months after the last drug administration. 6. Histologically confirmed (according to the World Health Organization (WHO) classification) mantle cell lymphoma. The diagnosis has to be confirmed by phenotypic expression of CD5, CD20 and cyclin D1 or the t(11;14) translocation (by cytogenetics and/or fluorescence in situ hybridization (FISH) and/or BCL1-IgH PCR) 7. Untreated MCL 8. Adequate renal function as demonstrated by a creatinine clearance \> 50 mL/min; calculated by Cockcroft Gault formula or Modification of Diet in Renal Disease (MDRD) 9. Adequate hepatic function per local laboratory reference range as follow: * Aspartate transaminase (AST) and alanine transaminase (ALT) \< 3.0 x upper limit of normal (ULN) * Bilirubin \< 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin) 10. Stage II-IV disease, measurable with at least lymph node \> 1.5 cm and requiring treatment in the opinion of the treating clinician 11. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2. 12. Life expectancy of more than 3 months. 13. For France: patient affiliated to any social security system
Exclusion criteria
1. Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification. 2. Impaired organ function (other than liver and renal) which will interfere with the treatment 3. Hemoglobin level \< 10g/dL; Neutrophil count \<1 G/L; Platelets \< 75 G/L (except if related to lymphoma then platelet must be \>50), 4. Major surgery within 28 days before enrollment 5. Known central nervous system lymphoma 6. History of stroke or intracranial hemorrhage within 6 months prior to enrollment. 7. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) 8. Requires treatment with strong CYP3A inhibitors 9. Vaccinated with live, attenuated vaccines within 6 months of enrollment (except COVID vaccine) 10. Known history of human immunodeficiency virus (HIV) 11. Evidence of other clinically significant uncontrolled condition(s) including but not limited to: * Uncontrolled and/or active systemic infection (viral, bacterial or fungal) * Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. HBs antigen negative, anti-HBs antibody + and antiHBc antibody -) and subjects with anti-HB-core antibody that are HBV DNA negative may participate 12. Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study 13. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator' opinion, could compromise the patient safety, interfere with the absorption or metabolism of treatment (Ibrutinib, CD20 Ab, venetoclax) or put the study outcomes at undue risk 14. Pregnant, planning to become pregnant, or lactating woman 15. Known hypersensitivity to study treatment (CD20 Ab, Ibrutinib, Venetoclax) or to any of the excipients 16. Known allergy to xanthine oxidase inhibitors or rasburicase 17. Known glucose-6-phosphate dehydrogenase (G6DP) deficiency 18. Known bleeding disorders 19. Severe prior reactions to monoclonal antibodies or with prior significant toxicity (other than thrombocytopenia) from Bcl-2 inhibitor 20. History of prior other malignancy with the exception of: * curatively treated basal cell carcinoma * curatively treated squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study * other curatively treated cancer and patient disease-free for over 5 years 21. Anti-cancer therapies including chemotherapy, radiotherapy or other investigational therapy, including targeted small molecule agents 22. Biological agents (e.g. monoclonal antibodies) for anti-neoplastic intent: excluded 30 days prior to first dose of venetoclax 23. Person deprived of his/her liberty by a judicial or administrative decision 24. Adult person under legal protection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Minimum residual disease (MRD) rate | 6 months | Minimum residual disease rate using droplet digital PCR (ddPCR) in bone marrow (BM) and/or peripheral blood (PB) at the end of induction |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of response | 5,5 years | time from attainment of Complete Response (CR) or Partial Response (PR) to the date of first documented disease progression, relapse or death from any cause |
| Disease free survival | 5,5 years | time from attainment of CR to the date of the first documented disease progression, relapse or death from any cause |
| Progression free survival (PFS) | 5,5 years | Progression free survival: time from randomization into the study to the first observation of documented clinical disease progression or death due to any cause |
| Overall survival (OS) | 5,5 years | Overall survival from the date of randomization to the date of death from any cause |
| Duration of MRD negativity | 5,5 years | time from the date of attainment the first negative MRD to the date of positive MRD |
| MRD rate | 6 months | MRD response using quantified PCR (qPCR) in PB and BM |
| Overall response rate (ORR) | 3 months | Overall response rate according to Lugano criteria |
| ORR | 6 months | Overall response rate according to Lugano criteria |
| Complete response rate (CRR) | 3 months | Complete response rate according to Lugano criteria |
| Delay from MRD positivity to clinical relapse | 5,5 years | time from the date of attainment the first positive MRD based on PB or BM to the first observation of documented disease progression or death due to any cause |
| CRR | 6 months | Complete response rate according to Lugano criteria |
Countries
Belgium, France, United Kingdom
Contacts
PRINCIPAL_INVESTIGATORSteven Le Gouill
Lymphoma Study Association
PRINCIPAL_INVESTIGATORToby Eyre
NCRI UK
PRINCIPAL_INVESTIGATORDavid Lewis
NCRI UK
Outcome results
None listed